IGC Pharma, Inc.
IGC
$0.29
$0.000.32%
AMEX
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 265.00K | 317.00K | 191.00K | 328.00K | 330.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 265.00K | 317.00K | 191.00K | 328.00K | 330.00K |
| Cost of Revenue | 217.00K | 262.00K | 92.00K | 174.00K | 176.00K |
| Gross Profit | 48.00K | 55.00K | 99.00K | 154.00K | 154.00K |
| SG&A Expenses | 1.44M | 1.24M | 1.41M | 1.21M | 619.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.05M | 2.78M | 3.09M | 2.23M | 1.79M |
| Operating Income | -2.78M | -2.46M | -2.90M | -1.91M | -1.46M |
| Income Before Tax | -2.94M | -2.40M | -1.82M | -1.60M | -1.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.94M | -2.40M | -1.82M | -1.60M | -1.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.94M | -2.40M | -1.82M | -1.60M | -1.20M |
| EBIT | -2.78M | -2.46M | -2.90M | -1.91M | -1.46M |
| EBITDA | -2.73M | -2.40M | -2.78M | -1.76M | -1.31M |
| EPS Basic | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 100.33M | 98.16M | 90.46M | 83.03M | 79.59M |
| Average Diluted Shares Outstanding | 100.33M | 98.16M | 90.46M | 83.03M | 79.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |